A detailed history of Royal Bank Of Canada transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Royal Bank Of Canada holds 8,894 shares of PRTA stock, worth $134,121. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,894
Previous 8,704 2.18%
Holding current value
$134,121
Previous $179,000 17.32%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $3,178 - $4,710
190 Added 2.18%
8,894 $148,000
Q2 2024

Aug 14, 2024

BUY
$19.54 - $26.15 $62,332 - $83,418
3,190 Added 57.85%
8,704 $179,000
Q1 2024

Nov 05, 2024

SELL
$24.75 - $40.66 $78,952 - $129,705
-3,190 Reduced 36.65%
5,514 $136,000
Q1 2024

May 15, 2024

SELL
$24.75 - $40.66 $108,132 - $177,643
-4,369 Reduced 44.21%
5,514 $136,000
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $45,880 - $74,294
1,420 Added 16.78%
9,883 $359,000
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $13,717 - $20,474
290 Added 3.55%
8,463 $408,000
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $75,768 - $123,386
-1,570 Reduced 16.11%
8,173 $558,000
Q1 2023

May 15, 2023

SELL
$46.97 - $58.27 $129,355 - $160,475
-2,754 Reduced 22.04%
9,743 $472,000
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $249,631 - $311,740
4,796 Added 62.28%
12,497 $752,000
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $129,121 - $311,153
-5,132 Reduced 39.99%
7,701 $467,000
Q2 2022

Aug 15, 2022

BUY
$22.73 - $39.98 $46,050 - $80,999
2,026 Added 18.75%
12,833 $348,000
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $136,063 - $221,243
-4,495 Reduced 29.38%
10,807 $395,000
Q4 2021

Feb 14, 2022

BUY
$42.11 - $73.26 $96,010 - $167,032
2,280 Added 17.51%
15,302 $756,000
Q3 2021

Nov 15, 2021

SELL
$48.2 - $78.89 $2.13 Million - $3.48 Million
-44,090 Reduced 77.2%
13,022 $928,000
Q2 2021

Aug 16, 2021

BUY
$21.63 - $57.65 $1.24 Million - $3.29 Million
57,112 New
57,112 $2.94 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $708M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.